Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2020

01-04-2020 | Computed Tomography | Original Article

Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma

Authors: Hongping Xia, Jianxiang Chen, Hengjun Gao, Shik Nie Kong, Amudha Deivasigamani, Ming Shi, Tian Xie, Kam M. Hui

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2020

Login to get access

Abstract

Purpose

To investigate the molecular mechanisms underlying the variable standard uptake value (SUV) of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) imaging in hepatocellular carcinoma (HCC) and whether hypoxia-induced glucose transporter expression contributes to the progression of HCC and the rate of glycolysis in HCC cells.

Materials and methods

Sixteen HCC specimens obtained from patients who underwent pre-treatment staging with 18F-FDG PET-CT imaging were divided into high maximum SUV (SUVmax > 8) and low SUVmax (SUVmax < 5) groups and employed for whole-genome gene expression profiling using GeneChip Human Genome U133 Plus 2.0 Arrays. The relationship between SUVmax and the expression of glucose transporters 1 and 3 (GLUT1 and GLUT3) was further validated using immunohistochemical analysis. The expression of GLUT1 and GLUT3 in different HCC cells under hypoxia and normoxia conditions were monitored by quantitative reverse transcription PCR (RT-qPCR). Glycolysis and FDG uptake by HCC cells were measured using the Seahorse XF glycolysis stress test and 18F-FDG PET-CT imaging. The effect of GLUT1 and GLUT3 on glucose uptake in HCC cells was examined using the fluorescent D-glucose analog 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-d-glucose (2-NBDG) followed by detection of fluorescence produced by the cells using flow cytometry.

Results

Glucose transporters are differentially expressed between samples from HCC patients with high and low SUVmax. In particular, over-expression of GLUT1 and GLUT3 in high SUVmax patients was correlated with high glucose uptake and overall survival. The expression of GLUT1 and GLUT3 was significantly induced by hypoxia in different HCC cells. High expression of GLUT1 and GLUT3 in HCC cells were correlated with high rates of glycolysis and 18F-FDG uptake. Therefore, our data suggested that hypoxia-induced glucose transporters expression could result in the variations of 18F-FDG PET-CT imaging and progression of HCC, contributing to more aggressive disease phenotypes like large tumor size, recurrence, and poor survival.

Conclusion

Over-expression of GLUT1 and GLUT3 significantly increase glucose uptake in HCC cells. Hypoxia-induced glucose transporters expression may therefore be a contributing variable in 18F-FDG PET-CT imaging and progression in HCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang T-W, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med. 2014;20:1138.CrossRef Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang T-W, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med. 2014;20:1138.CrossRef
2.
go back to reference Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRef Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRef
3.
go back to reference Fu Y, Ong L-C, Ranganath SH, Zheng L, Kee I, Zhan W, et al. A dual tracer 18F-FCH/18F-FDG PET imaging of an orthotopic brain tumor xenograft model. PLoS One. 2016;11:e0148123.CrossRef Fu Y, Ong L-C, Ranganath SH, Zheng L, Kee I, Zhan W, et al. A dual tracer 18F-FCH/18F-FDG PET imaging of an orthotopic brain tumor xenograft model. PLoS One. 2016;11:e0148123.CrossRef
4.
go back to reference Y-i K, Paeng JC, Cheon GJ, Suh K-S, Lee DS, Chung J-K, et al. Prediction of posttransplantation recurrence of hepatocellular carcinoma using metabolic and volumetric indices of 18F-FDG PET/CT. J Nucl Med. 2016;57:1045–51.CrossRef Y-i K, Paeng JC, Cheon GJ, Suh K-S, Lee DS, Chung J-K, et al. Prediction of posttransplantation recurrence of hepatocellular carcinoma using metabolic and volumetric indices of 18F-FDG PET/CT. J Nucl Med. 2016;57:1045–51.CrossRef
5.
go back to reference Sung PS, Park HL, Yang K, Hwang S, Song MJ, Jang JW, et al. 18 F–fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. Eur J Nucl Med Mol Imaging. 2018;45:384–91.CrossRef Sung PS, Park HL, Yang K, Hwang S, Song MJ, Jang JW, et al. 18 F–fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. Eur J Nucl Med Mol Imaging. 2018;45:384–91.CrossRef
6.
go back to reference Na SJ, Oh JK, Hyun SH, Lee JW, Hong IK, Song B-I, et al. 18F-FDG PET/CT can predict survival of advanced hepatocellular carcinoma patients: a multicenter retrospective cohort study. J Nucl Med. 2017;58:730–6.CrossRef Na SJ, Oh JK, Hyun SH, Lee JW, Hong IK, Song B-I, et al. 18F-FDG PET/CT can predict survival of advanced hepatocellular carcinoma patients: a multicenter retrospective cohort study. J Nucl Med. 2017;58:730–6.CrossRef
7.
go back to reference Lin C-Y, Liao C-W, Chu L-Y, Yen K-Y, Jeng L-B, Hsu C-N, et al. Predictive value of 18F-FDG PET/CT for vascular invasion in patients with hepatocellular carcinoma before liver transplantation. Clin Nucl Med. 2017;42:e183–e7.CrossRef Lin C-Y, Liao C-W, Chu L-Y, Yen K-Y, Jeng L-B, Hsu C-N, et al. Predictive value of 18F-FDG PET/CT for vascular invasion in patients with hepatocellular carcinoma before liver transplantation. Clin Nucl Med. 2017;42:e183–e7.CrossRef
8.
go back to reference Chalaye J, Costentin CE, Luciani A, Amaddeo G, Ganne-Carrié N, Baranes L, et al. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. J Hepatol. 2018;69:336–44.CrossRef Chalaye J, Costentin CE, Luciani A, Amaddeo G, Ganne-Carrié N, Baranes L, et al. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. J Hepatol. 2018;69:336–44.CrossRef
9.
go back to reference Lee M, Jeon JY, Neugent ML, Kim J-W, Yun M. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma. Clinical & Experimental Metastasis. 2017;34:251–60.CrossRef Lee M, Jeon JY, Neugent ML, Kim J-W, Yun M. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma. Clinical & Experimental Metastasis. 2017;34:251–60.CrossRef
10.
go back to reference Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, et al. Imaging tumour hypoxia with positron emission tomography. Br J Cancer. 2015;112:238.CrossRef Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, et al. Imaging tumour hypoxia with positron emission tomography. Br J Cancer. 2015;112:238.CrossRef
11.
go back to reference Zhang J-Z, Behrooz A, Ismail-Beigi F. Regulation of glucose transport by hypoxia. Am J Kidney Dis. 1999;34:189–202.CrossRef Zhang J-Z, Behrooz A, Ismail-Beigi F. Regulation of glucose transport by hypoxia. Am J Kidney Dis. 1999;34:189–202.CrossRef
12.
go back to reference Li X-F, Ma Y, Sun X, Humm JL, Ling CC, O'Donoghue JA. High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia. J Nucl Med. 2010;51:632–8.CrossRef Li X-F, Ma Y, Sun X, Humm JL, Ling CC, O'Donoghue JA. High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia. J Nucl Med. 2010;51:632–8.CrossRef
13.
go back to reference Lee JH, Park JY, Kim DY, Ahn SH, Han KH, Seo HJ, et al. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int. 2011;31:1144–9.CrossRef Lee JH, Park JY, Kim DY, Ahn SH, Han KH, Seo HJ, et al. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int. 2011;31:1144–9.CrossRef
14.
go back to reference Cho KJ, Choi NK, Shin MH, Chong AR. Clinical usefulness of FDG-PET in patients with hepatocellular carcinoma undergoing surgical resection. Annals of Hepato-Biliary-Pancreatic Surgery. 2017;21:194–8.CrossRef Cho KJ, Choi NK, Shin MH, Chong AR. Clinical usefulness of FDG-PET in patients with hepatocellular carcinoma undergoing surgical resection. Annals of Hepato-Biliary-Pancreatic Surgery. 2017;21:194–8.CrossRef
15.
go back to reference Wu B, Zhang Y, Tan H, Shi H. Value of 18 F-FDG PET/CT in the diagnosis of portal vein tumor thrombus in patients with hepatocellular carcinoma. Abdominal Radiology. 2019:1–6. Wu B, Zhang Y, Tan H, Shi H. Value of 18 F-FDG PET/CT in the diagnosis of portal vein tumor thrombus in patients with hepatocellular carcinoma. Abdominal Radiology. 2019:1–6.
16.
go back to reference Bains S, Behr S, Corvera C, Khan S, Win A, Seo Y, et al. SUVmax values in FDG-PET/CT scans of patients with HCC: a possible new prognostic factor. Journal of Nuclear Medicine. 2012;53:1308. Bains S, Behr S, Corvera C, Khan S, Win A, Seo Y, et al. SUVmax values in FDG-PET/CT scans of patients with HCC: a possible new prognostic factor. Journal of Nuclear Medicine. 2012;53:1308.
17.
go back to reference Soukupova J, Malfettone A, Hyroššová P, Hernández-Alvarez M-I, Peñuelas-Haro I, Bertran E, et al. Role of the Transforming Growth Factor-β in regulating hepatocellular carcinoma oxidative metabolism. Sci Rep. 2017;7:12486.CrossRef Soukupova J, Malfettone A, Hyroššová P, Hernández-Alvarez M-I, Peñuelas-Haro I, Bertran E, et al. Role of the Transforming Growth Factor-β in regulating hepatocellular carcinoma oxidative metabolism. Sci Rep. 2017;7:12486.CrossRef
18.
go back to reference Thorens B, Mueckler M. Glucose transporters in the 21st century. American Journal of Physiology-Endocrinology and Metabolism. 2009;298:E141–E5.CrossRef Thorens B, Mueckler M. Glucose transporters in the 21st century. American Journal of Physiology-Endocrinology and Metabolism. 2009;298:E141–E5.CrossRef
19.
go back to reference Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13:427–33.CrossRef Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13:427–33.CrossRef
20.
go back to reference Chen R, Li J, Zhou X, Liu J, Huang G. Fructose-1, 6-bisphosphatase 1 reduces 18F FDG uptake in hepatocellular carcinoma. Radiology. 2017;284:844–53.CrossRef Chen R, Li J, Zhou X, Liu J, Huang G. Fructose-1, 6-bisphosphatase 1 reduces 18F FDG uptake in hepatocellular carcinoma. Radiology. 2017;284:844–53.CrossRef
21.
go back to reference Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3314–9.CrossRef Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3314–9.CrossRef
22.
go back to reference Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32:792–7.CrossRef Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32:792–7.CrossRef
23.
go back to reference Bieze M, Klumpen H, Verheij J, Beuers U, Phoa S, van Gulik T. Diagnostic accuracy of 18F-methyl-choline PET/CT for intra-and extrahepatic hepatocellular carcinoma. Hepatology. 2014;59:996–1006.CrossRef Bieze M, Klumpen H, Verheij J, Beuers U, Phoa S, van Gulik T. Diagnostic accuracy of 18F-methyl-choline PET/CT for intra-and extrahepatic hepatocellular carcinoma. Hepatology. 2014;59:996–1006.CrossRef
24.
go back to reference Kuyumcu S, Has-Simsek D, Iliaz R, Sanli Y, Buyukkaya F, Akyuz F, et al. Evidence of prostate-specific membrane antigen expression in hepatocellular carcinoma using 68Ga-PSMA PET/CT. Clin Nucl Med. 2019;44:702–6.CrossRef Kuyumcu S, Has-Simsek D, Iliaz R, Sanli Y, Buyukkaya F, Akyuz F, et al. Evidence of prostate-specific membrane antigen expression in hepatocellular carcinoma using 68Ga-PSMA PET/CT. Clin Nucl Med. 2019;44:702–6.CrossRef
25.
go back to reference Sasikumar A, Joy A, Nanabala R, Pillai M, Thomas B, Vikraman K. 68Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:795–6.CrossRef Sasikumar A, Joy A, Nanabala R, Pillai M, Thomas B, Vikraman K. 68Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:795–6.CrossRef
26.
go back to reference Taneja S, Taneja R, Kashyap V, Jha A, Jena A. 68Ga-PSMA uptake in hepatocellular carcinoma. Clin Nucl Med. 2017;42:e69–70.CrossRef Taneja S, Taneja R, Kashyap V, Jha A, Jena A. 68Ga-PSMA uptake in hepatocellular carcinoma. Clin Nucl Med. 2017;42:e69–70.CrossRef
27.
go back to reference Koh YW, Park SY, Hyun SH, Lee SJ. Associations between PET textural features and GLUT1 expression, and the prognostic significance of textural features in lung adenocarcinoma. Anticancer Res. 2018;38:1067–71.PubMed Koh YW, Park SY, Hyun SH, Lee SJ. Associations between PET textural features and GLUT1 expression, and the prognostic significance of textural features in lung adenocarcinoma. Anticancer Res. 2018;38:1067–71.PubMed
28.
go back to reference Kawai T, Yasuchika K, Seo S, Higashi T, Ishii T, Miyauchi Y, et al. Identification of keratin 19–positive cancer stem cells associating human hepatocellular carcinoma using 18F-Fluorodeoxyglucose positron emission tomography. Clin Cancer Res. 2017;23:1450–60.CrossRef Kawai T, Yasuchika K, Seo S, Higashi T, Ishii T, Miyauchi Y, et al. Identification of keratin 19–positive cancer stem cells associating human hepatocellular carcinoma using 18F-Fluorodeoxyglucose positron emission tomography. Clin Cancer Res. 2017;23:1450–60.CrossRef
29.
go back to reference Patel D, Gara SK, Ellis RJ, Boufraqech M, Nilubol N, Millo C, et al. FDG PET/CT scan and functional adrenal tumors: a pilot study for lateralization. World J Surg. 2016;40:683–9.CrossRef Patel D, Gara SK, Ellis RJ, Boufraqech M, Nilubol N, Millo C, et al. FDG PET/CT scan and functional adrenal tumors: a pilot study for lateralization. World J Surg. 2016;40:683–9.CrossRef
30.
go back to reference Yoon M, Jung SJ, Kim TH, Ha TK, Urm S-H, Park JS, et al. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas. Endocr Res. 2016;41:64–9.CrossRef Yoon M, Jung SJ, Kim TH, Ha TK, Urm S-H, Park JS, et al. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas. Endocr Res. 2016;41:64–9.CrossRef
31.
go back to reference Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–7.PubMed Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–7.PubMed
32.
go back to reference Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 1998;12:149–62.CrossRef Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 1998;12:149–62.CrossRef
33.
go back to reference Ci-Ai Lin, Lin-Lin Chang, Hong Zhu, Qiao-Jun He, Bo Yang, (2018) Hypoxic microenvironment and hepatocellular carcinoma treatment. Hepatoma Research 4 (6):26CrossRef Ci-Ai Lin, Lin-Lin Chang, Hong Zhu, Qiao-Jun He, Bo Yang, (2018) Hypoxic microenvironment and hepatocellular carcinoma treatment. Hepatoma Research 4 (6):26CrossRef
Metadata
Title
Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma
Authors
Hongping Xia
Jianxiang Chen
Hengjun Gao
Shik Nie Kong
Amudha Deivasigamani
Ming Shi
Tian Xie
Kam M. Hui
Publication date
01-04-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04638-4

Other articles of this Issue 4/2020

European Journal of Nuclear Medicine and Molecular Imaging 4/2020 Go to the issue